Journal
ARCHIVES OF VIROLOGY
Volume 164, Issue 7, Pages 1805-1814Publisher
SPRINGER WIEN
DOI: 10.1007/s00705-019-04257-2
Keywords
-
Categories
Funding
- National Natural Science Foundation [31671035, 51473071, 21504034]
- National Significant New Drugs Creation Program
- Jiangsu Province Foundation [BK20161137, BE2016632, BK20170204]
- Jiangsu Provincial Medical Innovation Team
Ask authors/readers for more resources
The recombinant vaccinia virus VG9 and the STAT3 inhibitor Stattic were combined to kill cancer cells via both oncolytic activity and inhibition of STAT3 phosphorylation in cells. The combinatory anti-tumour activity of these compounds was superior to the activity of VG9 or Stattic alone in vivo. The inhibition of tumour growth occurred via increased apoptosis and autophagy pathways. Furthermore, the combinatory anti-tumour activity was more efficient than that of VG9 or Stattic alone on xenografts, especially in nude mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available